Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Prospective, randomized, double-blind, placebo controlled, 12-week, multicenter study. The
objective of the study is to evaluate the efficacy and safety of once daily administration of
atrasentan tablets compared to placebo in reducing residual albuminuria in Japanese Type 2
diabetic patients with nephropathy who are treated with the maximum tolerated labeled dose
for hypertension of a RAS (renin angiotensin system) inhibitor.